Key result
Subclinical LV dysfunction affects ~36% of hospitalized COVID-19 patients, with GLS improving by 30 days.
Why the study?
Myocardial injury is associated with mortality in COVID-19, but few echocardiographic data exist regarding subclinical left ventricular dysfunction identified by global longitudinal strain and its short-term evolution.
Observational (n=31)
No
Absolute Event Rate: -16.4% vs -13.2%
p-value: p=<0.01
Subclinical left ventricular dysfunction is common in noncritical hospitalized COVID-19 patients despite preserved ejection fraction, correlates with myocardial injury markers, and tends to improve within 30 days.
Subclinical LV dysfunction may be transient in noncritical COVID-19; leaves open whether GLS screening improves risk stratification or outcomes.
Background and Objectives: Available studies confirm myocardial injury and its association with mortality in patients with COVID-19, but few data have been reported from echocardiographic studies. The aim of this study was to identify subclinical left ventricular dysfunction by global longitudinal strain (GLS) and its evolution in the short term in hospitalized patients with COVID-19. Materials and Methods: Thirty-one consecutive noncritical patients admitted for COVID-19 were included. Information on demographics, laboratory results, comorbidities, and medications was collected. Transthoracic echocardiograms were performed using a Philips Affinity 50, at the acute stage and at a 30-day follow-up. Automated left ventricular GLS was measured using a Philips Qlab 13.0. A GLS of <–15.9% was defined as abnormal. Results: The mean age was 65 ± 15.2 years, and 61.3% of patients were male. Nine patients (29%) had elevated levels of high-sensitivity troponin I. Left ventricular ejection fraction was preserved in all; however, 11 of them (35.5%) showed reduced GLS. These patients had higher troponin levels (median, 23.7 vs. 3.2 ng/L; p < 0.05) and NT-proBNP (median, 753 vs. 81 pg/mL; p < 0.05). The multivariate analysis revealed that myocardial injury, defined as increased troponin, was significantly associated with GLS values (coefficient B; p < 0.05). Follow-up at 30 days showed an improvement in GLS values in patients with subclinical left ventricular dysfunction (−16.4 ± 2.07% vs. −13.2 ± 2.40%; p < 0.01), without changes in the normal GLS group. Conclusions: Subclinical left ventricular dysfunction is common in noncritical hospitalized patients with COVID-19 (one in every three patients), even with preserved left ventricular ejection fraction. This impairment tends to be reversible on clinical recovery.
No takes yet. Share an insight, caveat, or question.
Morillas-Blasco et al. (2023) conducted an observational in COVID-19 (n=31). COVID-19 with subclinical left ventricular dysfunction vs. Baseline (acute stage) was evaluated on Evolution of global longitudinal strain (GLS) at 30 days in patients with subclinical left ventricular dysfunction (p=<0.01). Subclinical left ventricular dysfunction affected 35.5% of noncritical hospitalized COVID-19 patients, with global longitudinal strain significantly improving from -13.2% to -16.4% at 30 days.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: